WHO classifies India triple-mutant Covid variant as global risk. which spreads more easily than original and able to evade vaccines

[dbc]

First of all US Pfizer don't owned the IP. It belongs to Moderna of Germany.

By agreeing to the proposal, Biden USA
1. has succeeded in hijacking the suggestion from India and South Africa. Indeed it did as now the Western Press only mentioned USA. It is now a US initiative.

2. knew that the negotiation would takes a long time and meanwhile hr would gain his political mileage at ither nations' exoense.
3. would then stop paying Germany for royalties they are paying to Germany.

Isn't that smart.
Only USA would think of that.
Germany which naturally objected is now immediately demonized.

not this again the IP for mRNA is owned by the University of Pennsylvania.

Mainz, Germany, November 5, 2018 – BioNTech AG, a rapidly growing biotechnology company focused on the development of immunotherapies for the precise and individualized treatment of cancer and prevention of infectious diseases and the University of Pennsylvania (Penn), Philadelphia, USA, today announced that they have entered into a strategic research collaboration. The goal of the exclusive, multi-year partnership is to develop novel nucleoside-modified mRNA vaccine candidates for the prevention and treatment of various infectious diseases.
Under the terms of the agreement, BioNTech and the lab of Drew Weissman, MD, PhD, at Penn will exchange their in-depth knowledge and experience in mRNA research and development to advance the discovery of novel vaccine candidates. Penn will be responsible for a dedicated preclinical research program from discovery through to the completion of IND-enabling studies in up to ten infectious disease indications. BioNTech will be eligible to receive an exclusive worldwide license to further develop and commercialize product candidates arising from the research collaboration. If proprietary Penn technology is part of a new mRNA-based vaccine, the university will be eligible to receive additional milestone payments and royalties from BioNTech. Detailed financial terms were not disclosed.

https://biontech.de/sites/default/f...oNTech-and-the-University-of-Pennsylvania.pdf